2024
Procedure Volume and Outcomes With WATCHMAN Left Atrial Appendage Occlusion
Friedman D, Du C, Zimmerman S, Tan Z, Lin Z, Vemulapalli S, Kosinski A, Piccini J, Pereira L, Minges K, Faridi K, Masoudi F, Curtis J, Freeman J. Procedure Volume and Outcomes With WATCHMAN Left Atrial Appendage Occlusion. Circulation Cardiovascular Interventions 2024, 17: e013466. PMID: 38889251, PMCID: PMC11189610, DOI: 10.1161/circinterventions.123.013466.Peer-Reviewed Original ResearchConceptsVolume-outcome relationshipLikelihood of procedural successLeft atrial appendage occlusionProcedural successProcedure volumeAppendage occlusionNational Cardiovascular Data Registry LAAO RegistryVolume quartilesLeft atrial appendage occlusion devicesThree-level hierarchical generalized linear modelsMinimum volume thresholdsWatchman FLX deviceProcedural success rateHierarchical generalized linear modelsAssociated with outcomePhysician volumeWATCHMAN procedureFLX deviceOcclusion deviceVolume thresholdCardiovascular proceduresPhysiciansHospitalNational analysisSuccess rateMedicare Coverage and Patient Out-of-Pocket Costs for Cardiovascular-Kidney-Metabolic Medications
Young G, Bansal K, Riello R, Clark K, Dhruva S, Faridi K, Desai N. Medicare Coverage and Patient Out-of-Pocket Costs for Cardiovascular-Kidney-Metabolic Medications. JAMA Network Open 2024, 7: e2412437. PMID: 38771578, PMCID: PMC11109768, DOI: 10.1001/jamanetworkopen.2024.12437.Peer-Reviewed Original Research
2023
Association Between Claims‐Defined Frailty and Outcomes Following 30 Versus 12 Months of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention: Findings From the EXTEND‐DAPT Study
Faridi K, Strom J, Kundi H, Butala N, Curtis J, Gao Q, Song Y, Zheng L, Tamez H, Shen C, Secemsky E, Yeh R. Association Between Claims‐Defined Frailty and Outcomes Following 30 Versus 12 Months of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention: Findings From the EXTEND‐DAPT Study. Journal Of The American Heart Association 2023, 12: e029588. PMID: 37449567, PMCID: PMC10382113, DOI: 10.1161/jaha.123.029588.Peer-Reviewed Original ResearchConceptsExtended duration dual antiplatelet therapyDuration dual antiplatelet therapyNet adverse clinical eventsDual antiplatelet therapyAdverse clinical eventsPercutaneous coronary interventionCoronary interventionClinical eventsNonfrail patientsAntiplatelet therapyFrail patientsClaims dataMonths of DAPTClaims-based indexYears of ageMajor bleedingCause mortalityMultivariable adjustmentOlder patientsDAPT studyResults PatientsBackground FrailtyMyocardial infarctionClinical trialsMedicare claimsTrends in Spending and Claims for P2Y12 Inhibitors by Medicare and Medicaid From 2015 to 2020
Essa M, Ross J, Dhruva S, Desai N, Yeh R, Faridi K. Trends in Spending and Claims for P2Y12 Inhibitors by Medicare and Medicaid From 2015 to 2020. Journal Of The American Heart Association 2023, 12: e028869. PMID: 37042289, PMCID: PMC10227267, DOI: 10.1161/jaha.122.028869.Peer-Reviewed Original Research
2022
Days at home after transcatheter or surgical aortic valve replacement in high-risk patients
Chung M, Butala N, Faridi K, Almarzooq Z, Liu D, Xu J, Song Y, Baron S, Shen C, Kazi D, Yeh R. Days at home after transcatheter or surgical aortic valve replacement in high-risk patients. American Heart Journal 2022, 255: 125-136. PMID: 36309128, DOI: 10.1016/j.ahj.2022.10.080.Peer-Reviewed Original ResearchConceptsSurgical aortic valve replacementTranscatheter aortic valve replacementHigh-risk patientsAortic valve replacementHigh-risk trialsValve replacementIndex hospitalizationRisk trialsLong-term acute care hospitalSelf-expanding bioprosthesisAcute care hospitalsSkilled nursing facilitiesPatient-centered perspectiveFirst yearIndex LOSTAVR patientsCare hospitalEmergency departmentObservation staysPostprocedural courseLandmark analysisMedicare feeNursing facilitiesService claimsPatientsDemographic and State-Level Trends in Mortality Due to Ischemic Heart Disease in the United States from 1999 to 2019
Essa M, Ghajar A, Delago A, Hammond-Haley M, Shalhoub J, Marshall D, Salciccioli JD, Sugeng L, Philips B, Faridi KF. Demographic and State-Level Trends in Mortality Due to Ischemic Heart Disease in the United States from 1999 to 2019. The American Journal Of Cardiology 2022, 172: 1-6. PMID: 35317929, DOI: 10.1016/j.amjcard.2022.02.016.Peer-Reviewed Original ResearchMeSH KeywordsBlack PeopleData CollectionEthnicityFemaleHispanic or LatinoHumansMaleMyocardial IschemiaUnited StatesConceptsAge-adjusted mortality ratesHigher age-adjusted mortality ratesMortality rateEpidemiologic Research databaseIschemic heart diseaseCrude mortality ratePublic health measuresBlack populationDisease careHeart diseaseHispanic ethnicityHispanic womenResearch DatabaseGreater relative decreaseHispanic menIHDMortality trendsSignificant geographic variationAge groupsHealth measuresDisease controlWhite womenWhite menMortalityMortality decrease
2021
Applicability of Transcatheter Aortic Valve Replacement Trials to Real-World Clinical Practice Findings From EXTEND-CoreValve
Butala NM, Secemsky E, Kazi DS, Song Y, Strom JB, Faridi KF, Brennan JM, Elmariah S, Shen C, Yeh RW. Applicability of Transcatheter Aortic Valve Replacement Trials to Real-World Clinical Practice Findings From EXTEND-CoreValve. JACC Cardiovascular Interventions 2021, 14: 2112-2123. PMID: 34620389, PMCID: PMC8855223, DOI: 10.1016/j.jcin.2021.08.006.Peer-Reviewed Original ResearchConceptsTranscatheter aortic valve replacement (TAVR) trialsReal-world patientsReal-world populationTrial patientsPivotal trialsClinical practiceTreatment effectsReplacement trialsAbsolute reductionClinical practice findingsU.S. clinical practiceCharacteristics of patientsCongestive heart failureTrial treatment effectPatient characteristicsTrial cohortHeart failureMedicare cohortAbsolute benefitConventional therapyClinical trialsInverse probability weightingMedicare patientsTAVRMedicare beneficiariesPrognosis of Claims‐ Versus Trial‐Based Ischemic and Bleeding Events Beyond 1 Year After Coronary Stenting
Butala NM, Faridi KF, Secemsky EA, Song Y, Curtis J, Gibson CM, Kazi D, Shen C, Yeh RW. Prognosis of Claims‐ Versus Trial‐Based Ischemic and Bleeding Events Beyond 1 Year After Coronary Stenting. Journal Of The American Heart Association 2021, 10: e018744. PMID: 33682431, PMCID: PMC8174225, DOI: 10.1161/jaha.120.018744.Peer-Reviewed Original ResearchConceptsUnadjusted mortality ratesIschemic eventsDAPT studyMortality rateEnd pointCox proportional hazards modelPercutaneous coronary interventionProportional hazards modelCardiovascular clinical trialsTrial adjudicationBleeding eventsCathPCI RegistryCoronary interventionCoronary stentingSimilar prognosisPrognostic significanceClinical eventsClinical trialsMedicare claimsAdministrative claimsMortality riskHazards modelPatientsPrognosisDeathComparability of Event Adjudication Versus Administrative Billing Claims for Outcome Ascertainment in the DAPT Study
Faridi KF, Tamez H, Butala NM, Song Y, Shen C, Secemsky EA, Mauri L, Curtis JP, Strom JB, Yeh RW. Comparability of Event Adjudication Versus Administrative Billing Claims for Outcome Ascertainment in the DAPT Study. Circulation Cardiovascular Quality And Outcomes 2021, 14: e006589. PMID: 33435731, PMCID: PMC7855905, DOI: 10.1161/circoutcomes.120.006589.Peer-Reviewed Original ResearchConceptsNegative predictive valuePositive predictive valueMyocardial infarctionPredictive valueDAPT studyClinical trialsAdjudicated eventsClaims dataNational Cardiovascular Data Registry CathPCI RegistryClinical events committeeTrial of patientsPercutaneous coronary interventionTrial end pointsKappa statisticsAdjudicated deathCathPCI RegistryCerebrovascular eventsCoronary interventionCumulative incidenceEvents committeeOutcome ascertainmentBilling claimsInpatient hospitalizationBleeding rateCardiovascular disease
2020
Left Ventricular Systolic Function and Inpatient Mortality in Patients Hospitalized with Coronavirus Disease 2019 (COVID-19)
Faridi KF, Hennessey KC, Shah N, Soufer A, Wang Y, Sugeng L, Agarwal V, Sharma R, Sewanan LR, Hur DJ, Velazquez EJ, McNamara RL. Left Ventricular Systolic Function and Inpatient Mortality in Patients Hospitalized with Coronavirus Disease 2019 (COVID-19). Journal Of The American Society Of Echocardiography 2020, 33: 1414-1415. PMID: 32951969, PMCID: PMC7442910, DOI: 10.1016/j.echo.2020.08.016.Peer-Reviewed Original ResearchUse of Administrative Claims Data to Estimate Treatment Effects for 30 Versus 12 Months of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention
Faridi KF, Tamez H, Strom JB, Song Y, Butala NM, Shen C, Secemsky EA, Mauri L, Curtis JP, Gibson CM, Yeh RW. Use of Administrative Claims Data to Estimate Treatment Effects for 30 Versus 12 Months of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention. Circulation 2020, 142: 306-308. PMID: 32687440, PMCID: PMC7374757, DOI: 10.1161/circulationaha.120.047729.Peer-Reviewed Original ResearchValidation of Administrative Claims to Ascertain Outcomes in Pivotal Trials of Transcatheter Aortic Valve Replacement
Butala NM, Strom JB, Faridi KF, Kazi DS, Zhao Y, Brennan JM, Popma JJ, Shen C, Yeh RW. Validation of Administrative Claims to Ascertain Outcomes in Pivotal Trials of Transcatheter Aortic Valve Replacement. JACC Cardiovascular Interventions 2020, 13: 1777-1785. PMID: 32682677, PMCID: PMC7444647, DOI: 10.1016/j.jcin.2020.03.049.Peer-Reviewed Original ResearchMeSH KeywordsAdministrative Claims, HealthcareAgedAged, 80 and overAortic Valve StenosisBioprosthesisClinical Trials as TopicData AccuracyData MiningDatabases, FactualFemaleHealth Services ResearchHeart Valve ProsthesisHumansInternational Classification of DiseasesMaleMedicarePostoperative ComplicationsReproducibility of ResultsTranscatheter Aortic Valve ReplacementTreatment OutcomeUnited StatesConceptsTranscatheter aortic valve replacementAortic valve replacementNegative predictive valuePositive predictive valueValve replacementPivotal trialsAdministrative claimsPredictive valueAortic valve reinterventionProcedural billing codesAcute kidney injuryPermanent pacemaker implantationKappa agreement statisticsBleeding eventsValve reinterventionKidney injuryTrial patientsPacemaker implantationProcedural complicationsOutcome ascertainmentTrial endpointsClinical endpointsMyocardial infarctionInpatient claimsClinical trialsUse of Administrative Claims to Assess Outcomes and Treatment Effect in Randomized Clinical Trials for Transcatheter Aortic Valve Replacement
Strom JB, Faridi KF, Butala NM, Zhao Y, Tamez H, Valsdottir LR, Brennan JM, Shen C, Popma JJ, Kazi DS, Yeh RW. Use of Administrative Claims to Assess Outcomes and Treatment Effect in Randomized Clinical Trials for Transcatheter Aortic Valve Replacement. Circulation 2020, 142: 203-213. PMID: 32436390, PMCID: PMC7672506, DOI: 10.1161/circulationaha.120.046159.Peer-Reviewed Original ResearchConceptsTrial primary end pointPrimary end pointEnd pointSURTAVI trialCause mortalitySecondary outcomesAdjudicated outcomesClinical trialsTrial dataSecondary trial end pointsTranscatheter aortic valve replacementTreatment effectsClaims-based outcomesAortic valve replacementTrial end pointsRandomized clinical trialsMedicare inpatient claimsCardiovascular clinical trialsYears of ageSAVR patientsValve replacementTreatment armsInpatient claimsProcedural outcomesAdministrative claimsPhysician and Hospital Utilization of P2Y12 Inhibitors in ST-Segment–Elevation Myocardial Infarction in the United States
Faridi KF, Garratt KN, Kennedy KF, Maddox TM, Secemsky EA, Butala NM, Yeh RW. Physician and Hospital Utilization of P2Y12 Inhibitors in ST-Segment–Elevation Myocardial Infarction in the United States. Circulation Cardiovascular Quality And Outcomes 2020, 13: e006275. PMID: 32156164, DOI: 10.1161/circoutcomes.119.006275.Peer-Reviewed Original ResearchMeSH KeywordsAgedCardiologistsCardiology Service, HospitalClopidogrelDrug UtilizationFemaleHemorrhageHumansMaleMiddle AgedPatient DischargePercutaneous Coronary InterventionPlatelet Aggregation InhibitorsPractice Patterns, Physicians'Prasugrel HydrochloridePurinergic P2Y Receptor AntagonistsReceptors, Purinergic P2Y12RegistriesRetrospective StudiesRisk AssessmentRisk FactorsST Elevation Myocardial InfarctionTicagrelorTime FactorsTreatment OutcomeUnited StatesConceptsST-segment elevation myocardial infarctionP2Y12 inhibitor usePotent P2Y12 inhibitorsP2Y12 inhibitorsSTEMI patientsMyocardial infarctionInhibitor useClopidogrel usePrior percutaneous coronary interventionNew P2Y12 inhibitorsSubstantial hospital variationUse of ticagrelorElevation myocardial infarctionPercutaneous coronary interventionRisk of deathStrongest clinical predictorsNational utilization ratesBackground TicagrelorHospital quartilesCoronary interventionPatient characteristicsClinical predictorsTicagrelor useHospital variationRetrospective study
2019
Comparison of Clinical Trials and Administrative Claims to Identify Stroke Among Patients Undergoing Aortic Valve Replacement
Strom JB, Zhao Y, Faridi KF, Tamez H, Butala NM, Valsdottir LR, Curtis J, Brennan JM, Shen C, Boulware M, Popma JJ, Yeh RW. Comparison of Clinical Trials and Administrative Claims to Identify Stroke Among Patients Undergoing Aortic Valve Replacement. Circulation Cardiovascular Interventions 2019, 12: e008231. PMID: 31694411, PMCID: PMC7212938, DOI: 10.1161/circinterventions.119.008231.Peer-Reviewed Original ResearchMeSH KeywordsAdministrative Claims, HealthcareAgedAged, 80 and overAortic ValveAortic Valve StenosisBrain IschemiaClinical Trials as TopicDatabases, FactualFemaleHeart Valve Prosthesis ImplantationHumansIschemic Attack, TransientMaleMedicareRisk AssessmentRisk FactorsStrokeTime FactorsTranscatheter Aortic Valve ReplacementTreatment OutcomeUnited StatesConceptsNegative predictive valueAortic valve replacementCerebrovascular eventsInternational ClassificationPositive predictive valuePredictive valueValve replacementNinth RevisionClinical trialsTenth RevisionBilling codesKaplan-Meier estimatesMedicare inpatient claimsSURTAVI trialClinical event adjudicationDevastating complicationIschemic strokeNeurological eventsCerebrovascular diseaseBilling claimsInpatient claimsEvent adjudicationAdministrative claimsHigh riskTrial participantsGeographic Patterns of Growth for Transcatheter Aortic Valve Replacement in the United States
Kundi H, Faridi KF, Wang Y, Wadhera RK, Valsdottir LR, Popma JJ, Kramer DB, Yeh RW. Geographic Patterns of Growth for Transcatheter Aortic Valve Replacement in the United States. Circulation 2019, 140: 969-971. PMID: 31498696, PMCID: PMC6736630, DOI: 10.1161/circulationaha.119.040788.Peer-Reviewed Original Research
2018
The Value of Claims-Based Nontraditional Risk Factors in Predicting Long-term Mortality After MitraClip Procedure
Kundi H, Popma JJ, Valsdottir LR, Shen C, Faridi KF, Pinto DS, Yeh RW. The Value of Claims-Based Nontraditional Risk Factors in Predicting Long-term Mortality After MitraClip Procedure. Canadian Journal Of Cardiology 2018, 34: 1648-1654. PMID: 30527154, PMCID: PMC6424362, DOI: 10.1016/j.cjca.2018.10.002.Peer-Reviewed Original ResearchConceptsNontraditional risk factorsLong-term mortalityNoncardiac risk factorsMitral valve repairRisk factorsValve repairMitraClip procedureClaims dataLong-term mortality riskPercutaneous mitral valve repairTranscatheter mitral valve repairPredicting Long-Term MortalityCardiac risk factorsPresentation characteristicsCox regression modelAdministrative claims dataRisk prediction modelMedian followMitraClip implantationModel discriminationMortality riskClaims codesMedicare feePatientsService beneficiariesUtilization, In-Hospital Mortality, and 30-Day Readmission After Percutaneous Mitral Valve Repair in the United States Shortly After Device Approval
Faridi KF, Popma JJ, Strom JB, Shen C, Choi E, Yeh RW. Utilization, In-Hospital Mortality, and 30-Day Readmission After Percutaneous Mitral Valve Repair in the United States Shortly After Device Approval. The American Journal Of Cardiology 2018, 121: 1365-1372. PMID: 29627105, DOI: 10.1016/j.amjcard.2018.02.016.Peer-Reviewed Original ResearchConceptsPercutaneous mitral valve repairMitral valve repairValve repairHospital volumeClinical comorbiditiesReduced hospital readmissionsHospital mortality rateDays of dischargeIn-Hospital MortalityNationwide Readmissions DatabaseAdministrative claims databaseHospital readmission ratesRoutine clinical practiceDevice approvalCause mortalityHospital deathMultivariable adjustmentPatient demographicsReadmission ratesHospital readmissionMitraClip deviceClaims databaseHospital characteristicsRisk factorsProcedural volume
2017
Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Therapy
Hess GP, Natarajan P, Faridi KF, Fievitz A, Valsdottir L, Yeh RW. Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Therapy. Circulation 2017, 136: 2210-2219. PMID: 29084735, PMCID: PMC5716860, DOI: 10.1161/circulationaha.117.028430.Peer-Reviewed Original ResearchMeSH KeywordsAdministrative Claims, HealthcareAgedAtherosclerosisCost-Benefit AnalysisDrug CostsElectronic Health RecordsEligibility DeterminationFemaleHumansHyperlipoproteinemia Type IIHypolipidemic AgentsInsurance, Health, ReimbursementInsurance, Pharmaceutical ServicesMaleMedicareMiddle AgedPCSK9 InhibitorsProcess Assessment, Health CareProprotein Convertase 9Retrospective StudiesSerine Proteinase InhibitorsTreatment OutcomeUnited StatesConceptsProprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitorsAtherosclerotic cardiovascular diseasePCSK9i prescriptionsPayer typeCardiovascular diseaseProprotein convertase subtilisin/kexin type 9 inhibitor therapyHigher low-density lipoprotein cholesterol levelsSubtilisin/kexin type 9 inhibitorsLow-density lipoprotein cholesterol levelsClinical atherosclerotic cardiovascular diseaseDrug's high costNonprimary care providersLipoprotein cholesterol levelsDescriptive cohort studyElectronic medical recordsPCSK9i therapyPrescription approvalThird-party payersStatin useClinical characteristicsStatin intoleranceCohort studyInhibitor therapyPharmacy claimsPrescription claims
2016
Timing of First Postdischarge Follow-up and Medication Adherence After Acute Myocardial Infarction
Faridi KF, Peterson ED, McCoy LA, Thomas L, Enriquez J, Wang TY. Timing of First Postdischarge Follow-up and Medication Adherence After Acute Myocardial Infarction. JAMA Cardiology 2016, 1: 147. PMID: 27437885, DOI: 10.1001/jamacardio.2016.0001.Peer-Reviewed Original ResearchConceptsAcute myocardial infarctionMedication adherenceClinic visitsHospital dischargeMyocardial infarctionIntervention Outcomes Network RegistryPlatelet P2Y12 receptor inhibitorsAngiotensin-converting enzyme inhibitorAcute Coronary TreatmentFirst outpatient followImproved care transitionsP2Y12 receptor inhibitorsPostdischarge Follow-upAngiotensin receptor blockersSecondary prevention therapiesLong-term prognosisLow medication adherencePatient medication adherenceProportion of daysLower household incomeGuidelines hospitalsReceptor blockersAcute MIClinical characteristicsCoronary Treatment